Phase II trial data showed AcelRx Pharmaceuticals' experimental pain drug ARX-04 met the main study goal of reducing acute pain at a dosage of 30 micrograms but not at 20 mcg. The study compared both dosages against a placebo.
Experimental pain drug effective at higher dose, study shows
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group